查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1467797

2024-2032 年代谢组学市场报告（按产品、适应症、应用和地区）

Metabolomics Market Report by Product, Indication, Application, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3个工作天内

价格

2023年全球IMARC Group组学市场规模达27亿美元。对个人化医疗不断增长的需求、慢性病盛行率的上升、製药和生物技术研究的扩大以及对先进生物标记和药物发现解决方案的需求是推动市场的一些主要因素。

代谢组学是生命科学领域的一个前沿领域，专注于生物系统内称为代谢物的小分子的综合研究。这些代谢物包括糖、胺基酸、脂质和其他细胞化合物等物质，它们在各种生物过程中发挥着至关重要的作用。代谢组学采用先进的分析技术（例如质谱法和核磁共振波谱法）来识别和量化这些代谢物。透过这样做，它可以深入了解有机体的代谢状态，提供有关健康、疾病、药物反应和环境影响的有价值的资讯。

全球代谢组学市场正在经历强劲成长，这主要是由于人们越来越认识到这种化合物在个人化医疗和医疗保健中发挥的关键作用。与此一致的是，代谢组学提供了一个强大的工具来了解个人独特的代谢特征，从而实现更精确的诊断、治疗选择和量身定制的医疗保健计划，从而加强市场成长。此外，慢性病盛行率的增加以及早期疾病检测和预防的需求正在推动对代谢组学技术的需求，为市场扩张创造了积极的前景。除此之外，广泛采用这些技术来识别与疾病相关的代谢生物标记物，促进早期介入和监测，正在促进市场的成长。此外，製药和生物技术研究的扩展，加上药物发现和开发的推动，正在推动对代谢组学的需求，以阐明药物机制、预测药物疗效和评估安全性。

代谢组学市场趋势/驱动因素：

个人化医疗的进步

代谢组学市场最重要的驱动力之一是个人化医疗的重要性日益增加。医疗保健正在摆脱一刀切的方法，代谢组学在为个别患者量身定制治疗方法方面发挥关键作用。这种转变很大程度上是由于人们认识到仅靠遗传变异并不能完全了解个人的健康状况。代谢组学透过捕捉个体代谢特征的动态变化来补充基因组学，反映他们对疾病、药物和环境因素的独特反应。因此，代谢组学使医疗保健提供者能够做出更精确的诊断、选择个人化的治疗方案并监测治疗反应。例如，在癌症治疗中，代谢组学可以识别患者肿瘤中失调的特定代谢途径，帮助肿瘤学家选择最有效的疗法。

慢性病盛行率上升

糖尿病、心血管疾病和肥胖等慢性疾病的全球负担不断升级，是代谢组学市场的另一个重要驱动力。代谢组学为早期疾病检测、风险评估和监测提供了强大的工具。透过分析代谢生物标记物，研究人员和临床医生可以识别个体代谢特征的细微变化，这些变化可能先于疾病的临床表现。这种早期预警系统对于实施预防措施、在疾病发展的最早阶段开始治疗以及追踪疾病进展至关重要。此外，由于与生活方式相关的因素导致慢性疾病的增加，代谢组学可以揭示饮食选择、身体活动和环境暴露如何影响个人的代谢健康。

製药和生物技术研究

製药和生物技术领域越来越依赖代谢组学来增强药物发现和开发过程。代谢组学提供了对药物机制、功效和安全性的见解，从而加速了药物开发流程。研究人员利用代谢组学来识别和验证药物标靶，评估潜在候选药物的代谢效应，并预测其药物动力学和毒性。这些资讯有助于简化药物开发流程，减少代价高昂的后期失败，并提高将创新疗法推向市场的机会。此外，代谢组学对于了解药物交互作用、优化给药方案以及在临床试验期间监测患者反应至关重要，有助于药物开发工作的整体效率和成功。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球代谢组学市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依产品

  • 代谢组学仪器
    • 市场走向
    • 市场预测
  • 代谢组学生物资讯学工具与服务
    • 市场走向
    • 市场预测

第 7 章：市场区隔：依迹象

  • 癌症
    • 市场走向
    • 市场预测
  • 心血管疾病
    • 市场走向
    • 市场预测
  • 神经系统疾病
    • 市场走向
    • 市场预测
  • 先天性代谢缺陷
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：市场区隔：按应用

  • 生物标记和药物发现
    • 市场走向
    • 市场预测
  • 毒理学
    • 市场走向
    • 市场预测
  • 营养基因体学
    • 市场走向
    • 市场预测
  • 个人化医疗
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太地区
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第13章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Agilent Technologies Inc.
    • Biocrates Life Sciences AG
    • Bio-Rad Laboratories Inc.
    • Bruker Corporation
    • Danaher Corporation
    • Human Metabolome Technologies Inc.
    • Metabolon Inc.
    • Shimadzu Corporation
    • Thermo Fisher Scientific Inc.
    • Waters Corporation
Product Code: SR112024A2024

The global metabolomics market size reached US$ 2.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.5 Billion by 2032, exhibiting a growth rate (CAGR) of 10.1% during 2024-2032. The growing demand for personalized medicine, rising prevalence of chronic diseases, expanding pharmaceutical and biotechnology research, and the need for advanced biomarker and drug discovery solutions are some of the major factors propelling the market.

Metabolomics is a cutting-edge field in the realm of life sciences that focuses on the comprehensive study of small molecules called metabolites within biological systems. These metabolites include substances such as sugars, amino acids, lipids, and other cellular compounds, and they play crucial roles in various biological processes. Metabolomics employ advanced analytical techniques, such as mass spectrometry and nuclear magnetic resonance spectroscopy, to identify and quantify these metabolites. By doing so, it offers insights into an organism's metabolic state, providing valuable information about health, disease, drug responses, and environmental influences.

The global metabolomics market is experiencing robust growth, primarily driven by the growing recognition of the pivotal role that this compound plays in personalized medicine and healthcare. In line with this, metabolomics provides a powerful tool for understanding an individual's unique metabolic profile, enabling more precise diagnosis, treatment selection, and tailored healthcare plans, thereby strengthening the market growth. Moreover, the increasing prevalence of chronic diseases and the need for early disease detection and prevention are boosting demand for metabolomics technologies, creating a positive outlook for market expansion. In addition to this, the widespread adoption of these technologies to identify metabolic biomarkers associated with diseases, facilitating early intervention and monitoring, is contributing to the market's growth. Furthermore, the expansion of pharmaceutical and biotechnology research, coupled with the drive for drug discovery and development, is fueling demand for metabolomics to elucidate drug mechanisms, predict drug efficacy, and assess safety.

Metabolomics Market Trends/Drivers:

Advancements in personalized medicine

One of the foremost drivers of the metabolomics market is the increasing importance of personalized medicine. Healthcare is moving away from a one-size-fits-all approach, and metabolomics plays a pivotal role in tailoring treatments to individual patients. This shift is largely due to the recognition that genetic variations alone do not provide a complete understanding of an individual's health. Metabolomics complements genomics by capturing dynamic changes in an individual's metabolic profile, reflecting their unique response to diseases, drugs, and environmental factors. As a result, metabolomics enables healthcare providers to make more precise diagnoses, select personalized treatment options, and monitor therapeutic responses. For example, in cancer treatment, metabolomics can identify specific metabolic pathways that are dysregulated in a patient's tumor, helping oncologists choose the most effective therapies.

Rising prevalence of chronic diseases

The escalating global burden of chronic diseases including diabetes, cardiovascular disorders, and obesity is another significant driver of the metabolomics market. Metabolomics provides a powerful tool for early disease detection, risk assessment, and monitoring. By analyzing metabolic biomarkers, researchers and clinicians can identify subtle changes in an individual's metabolic profile that may precede the clinical manifestation of a disease. This early warning system is crucial for implementing preventive measures, initiating treatments at the earliest stages of disease development, and tracking disease progression. Additionally, as lifestyle-related factors contribute to the rise in chronic diseases, metabolomics can shed light on how dietary choices, physical activity, and environmental exposures impact an individual's metabolic health.

Pharmaceutical and biotechnology research

The pharmaceutical and biotechnology sectors are increasingly relying on metabolomics to enhance drug discovery and development processes. Metabolomics offers insights into drug mechanisms, efficacy, and safety, thereby accelerating the drug development pipeline. Researchers use metabolomics to identify and validate drug targets, assess the metabolic effects of potential drug candidates, and predict their pharmacokinetics and toxicity. This information helps streamline the drug development process, reduce costly late-stage failures, and improve the chances of bringing innovative therapies to market. Moreover, metabolomics is crucial for understanding drug interactions, optimizing dosing regimens, and monitoring patient responses during clinical trials, contributing to the overall efficiency and success of drug development efforts.

Metabolomics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global metabolomics market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, indication, and application.

Breakup by Product:

Metabolomics Instruments

Metabolomics Bioinformatics Tools and Services

Metabolomics bioinformatics tools and services dominate the market

The report has provided a detailed breakup and analysis of the market based on the product. This includes metabolomics instruments and metabolomics bioinformatics tools and services. According to the report, metabolomics bioinformatics tools and services represented the largest segment.

The demand for metabolomics bioinformatic tools and services is mainly propelled by the complexity and volume of data generated in metabolomics research. Metabolomics experiments produce vast datasets with intricate molecular information, making data analysis and interpretation a significant challenge. Besides this, metabolomics bioinformatic tools and services are essential for processing, managing, and extracting meaningful insights from this wealth of data. Furthermore, the integration of multi-omics data, including genomics, proteomics, and metabolomics, is becoming increasingly crucial to gain a holistic understanding of biological systems. To harness the full potential of metabolomics data, researchers require sophisticated software solutions and expert services that can handle data preprocessing, statistical analysis, pathway mapping, and biomarker identification. As metabolomics continues to expand its applications in diverse fields, the demand for bioinformatic tools and services is set to rise, enabling researchers to unlock the valuable information hidden within their datasets.

Breakup by Indication:

Cancer

Cardiovascular Disorders

Neurological Disorders

Inborn Errors of Metabolism

Others

Cancer holds the largest share in the market

A detailed breakup and analysis of the market based on the indication has also been provided in the report. This includes cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and others. According to the report, cancer accounted for the largest market share.

The urgent need for more precise and early detection methods, as well as personalized treatment strategies in cancer research and diagnostics is strengthening the demand for metabolomics. They offer a unique advantage in cancer studies by providing a real-time snapshot of an individual's metabolic profile, allowing for the identification of specific metabolic alterations associated with different types and stages of cancer. These metabolic signatures can serve as potential biomarkers for early cancer detection, enabling clinicians to detect malignancies at a more treatable stage. Furthermore, as cancer treatment often leads to metabolic changes and varying responses in patients, metabolomics can assist in tailoring therapeutic approaches by monitoring how a patient's metabolism reacts to specific cancer treatments. This personalized approach has the potential to enhance treatment outcomes and minimize adverse effects, driving the demand for metabolomics applications in the field of oncology.

Breakup by Application:

Biomarker and Drug Discovery

Toxicology

Nutrigenomics

Personalized Medicine

Others

Biomarker and drug discovery dominates the market

The report has provided a detailed breakup and analysis of the market based on the application. This includes biomarker and drug discovery, toxicology, nutrigenomics, personalized medicine, and others. According to the report, biomarker and drug discovery represented the largest segment.

The burgeoning demand for metabolomics in biomarker and drug discovery applications is driven by its unparalleled ability to unveil novel biomarkers and therapeutic targets. Metabolomics allows researchers to delve deep into an organism's biochemical landscape, identifying subtle metabolic changes associated with diseases and drug responses that may go unnoticed by other omics techniques. This capability is invaluable in biomarker discovery, where metabolomics can pinpoint specific metabolites indicative of disease presence, progression, or treatment efficacy. Additionally, in drug discovery, metabolomics plays a pivotal role in elucidating drug mechanisms and assessing potential drug candidates' safety profiles by uncovering their metabolic impact. By providing a comprehensive view of the intricate interactions within biological systems, metabolomics accelerates the identification of promising drug targets, expedites the development of new therapies, and minimizes the risk of late-stage drug failures, thereby fueling the demand for metabolomics in these critical areas of research.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest metabolomics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America boasts a thriving biopharmaceutical and healthcare industry, characterized by substantial investments in research and development (R&D). This robust ecosystem fuels the demand for metabolomics technologies in drug discovery and personalized medicine applications, as pharmaceutical companies seek innovative solutions to expedite drug development and enhance patient care. Concurrent with this, the region's healthcare infrastructure places a strong emphasis on precision medicine, with government initiatives and healthcare institutions increasingly recognizing the potential of metabolomics for tailoring treatments and improving patient outcomes. Furthermore, collaborations between academic research institutions and industry players in North America have paved the way for cutting-edge metabolomics research, further propelling the market's growth. These factors, combined with a favorable regulatory environment, position North America as a key hub for metabolomics innovation and adoption, driving the market forward.

Competitive Landscape:

The competitive landscape of the global metabolomics market is dynamic and characterized by intense competition among both established players and emerging companies. Leading companies dominate the market with their comprehensive portfolios of metabolomics instruments, software, and services. These industry giants focus on continuous innovation, strategic partnerships, and acquisitions to expand their market presence and offer integrated solutions to customers. Additionally, academic institutions and research organizations contribute significantly to the market by developing cutting-edge metabolomics technologies and methodologies and fostering collaborations with industry stakeholders. Emerging startups, specializing in niche metabolomics applications, are also gaining traction by introducing innovative tools and services, enhancing competition and driving market growth. Furthermore, the market's global nature makes it highly competitive on a regional basis, with regional players catering to specific geographical preferences and regulations.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Agilent Technologies Inc.

Biocrates Life Sciences AG

Bio-Rad Laboratories Inc.

Bruker Corporation

Danaher Corporation

Human Metabolome Technologies Inc.

Metabolon Inc.

Shimadzu Corporation

Thermo Fisher Scientific Inc.

Waters Corporation

Recent Developments:

In June 2021, Bruker Corporation unveiled the FluoroTypeSARS-CoV-2 Varied Q assay, a quantitative Liquid Array mid-plexPCR panel that identifies the presence of the virus and detects key mutations, allowing laboratories and hospitals to routinely distinguish between major viral variants in positive samples.

In June 2021, Thermo Fischer Scientific launched the Orbitrap IQ-X Tribrid mass spectrometer, the latest in their Next-Generation MS-Based Solutions lineup, designed specifically to elucidate intricate chemical structures for precise compound identification.

Key Questions Answered in This Report:

  • How has the global metabolomics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global metabolomics market?
  • What is the impact of each driver, restraint, and opportunity on the global metabolomics market?
  • What are the key regional markets?
  • Which countries represent the most attractive metabolomics market?
  • What is the breakup of the market based on the product?
  • Which is the most attractive product in the metabolomics market?
  • What is the breakup of the market based on the indication?
  • Which is the most attractive indication in the metabolomics market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the metabolomics market?
  • What is the competitive structure of the global metabolomics market?
  • Who are the key players/companies in the global metabolomics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Metabolomics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Metabolomics Instruments
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Metabolomics Bioinformatics Tools and Services
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cardiovascular Disorders
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Neurological Disorders
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Inborn Errors of Metabolism
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Biomarker and Drug Discovery
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Toxicology
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Nutrigenomics
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Personalized Medicine
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Agilent Technologies Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Biocrates Life Sciences AG
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
    • 13.3.3 Bio-Rad Laboratories Inc.
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Bruker Corporation
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
    • 13.3.5 Danaher Corporation
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Human Metabolome Technologies Inc.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
    • 13.3.7 Metabolon Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
    • 13.3.8 Shimadzu Corporation
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Thermo Fisher Scientific Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Waters Corporation
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Metabolomics Market: Major Drivers and Challenges
  • Figure 2: Global: Metabolomics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Metabolomics Market: Breakup by Product (in %), 2023
  • Figure 4: Global: Metabolomics Market: Breakup by Indication (in %), 2023
  • Figure 5: Global: Metabolomics Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Metabolomics Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Metabolomics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 8: Global: Metabolomics (Metabolomics Instruments) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Metabolomics (Metabolomics Instruments) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Metabolomics (Metabolomics Bioinformatics Tools and Services) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Metabolomics (Metabolomics Bioinformatics Tools and Services) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Metabolomics (Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Metabolomics (Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Metabolomics (Cardiovascular Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Metabolomics (Cardiovascular Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Metabolomics (Neurological Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Metabolomics (Neurological Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Metabolomics (Inborn Errors of Metabolism) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Metabolomics (Inborn Errors of Metabolism) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Metabolomics (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Metabolomics (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Metabolomics (Biomarker and Drug Discovery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Metabolomics (Biomarker and Drug Discovery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Metabolomics (Toxicology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Metabolomics (Toxicology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Metabolomics (Nutrigenomics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Metabolomics (Nutrigenomics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Metabolomics (Personalized Medicine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Metabolomics (Personalized Medicine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Metabolomics (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Metabolomics (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: North America: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: North America: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: United States: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: United States: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Canada: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Canada: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Asia Pacific: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Asia Pacific: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: China: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: China: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Japan: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Japan: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: India: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: India: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: South Korea: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: South Korea: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Australia: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Australia: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Indonesia: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Indonesia: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Others: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Others: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Europe: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Europe: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Germany: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Germany: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: France: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: France: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: United Kingdom: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: United Kingdom: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Italy: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Italy: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Spain: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Spain: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Russia: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Russia: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Latin America: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Latin America: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Brazil: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Brazil: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Mexico: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Mexico: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Middle East and Africa: Metabolomics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Middle East and Africa: Metabolomics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Global: Metabolomics Industry: SWOT Analysis
  • Figure 81: Global: Metabolomics Industry: Value Chain Analysis
  • Figure 82: Global: Metabolomics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Metabolomics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Metabolomics Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Metabolomics Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 4: Global: Metabolomics Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Metabolomics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Metabolomics Market: Competitive Structure
  • Table 7: Global: Metabolomics Market: Key Players